Background: Burdensome symptoms of allergic rhinitis (AR) include nasal and ocular symptoms such as itching, tearing and redness. Intranasal corticosteroids are efficacious in the treatment of nasal symptoms of AR. Objective: It was the aim of this study to determine the efficacy of the intranasal corticosteroid mometasone furoate nasal spray (MFNS) in relieving ocular symptoms associated with seasonal AR (SAR). Methods: Ocular symptom data were analyzed for subjects ≧12 years of age, randomized to MFNS 200 µg q.d. (n = 176) or placebo (n = 177) in a placebo-controlled, double-blind clinical trial. Post hoc efficacy analysis assessed the mean change from baseline in subject-reported total ocular symptom scores (TOSS) averaged over the treatment period. Results: Mean baseline TOSS was 4.91 for the MFNS group and comparable (5.05) for the placebo group – combined average for individual symptoms such as itching, tearing and redness ranged from 0 (no symptoms) to 9 (all symptoms, severe). Mean change from baseline in TOSS averaged over days 1–15 was –1.42 for the MFNS group and –0.94 for the placebo group (p = 0.02), for an observed treatment difference of 0.49 (statistical data rounded to 2 decimal positions). Improvement in individual symptoms (eye itching, tearing and redness) contributed to this treatment effect; the greatest improvement occurred with tearing, which decreased –0.52 from the baseline score 1.59 in the MFNS group and –0.31 from 1.67 in those receiving placebo (p < 0.01), for an observed treatment difference of 0.21. Treatment with MFNS was safe and well tolerated. Conclusion: MFNS is effective in reducing ocular symptoms of SAR, in addition to its established efficacy in reducing nasal symptoms of SAR.

1.
Juniper EF: Rhinitis management: the patient’s perspective. Clin Exp Allergy 1998;28:34–38.
2.
Bousquet J: From allergic rhinitis and its impact on asthma (ARIA) in collaboration with the World Health Organization (WHO). J Allergy Clin Immunol 2001;108:S147–S336.
3.
Benincasa C, Lloyd RS: Evaluation of fluticasone propionate aqueous nasal spray taken alone and in combination with cetirizine in the prophylactic treatment of seasonal allergic rhinitis. Drug Invest 1994;8:225–233.
4.
Wuthrich B, Brignoli R, Canevascini M, Gerber M: Epidemiological survey in hay fever patients: symptom prevalence and severity and influence on patient management. Schweiz Med Wochenschr 1998;128:139–143.
5.
Singh K, Bielory L: Epidemiology of ocular allergy symptoms in United States adults (1988–1994). Poster Annu Meet Am Coll Asthma Allergy Immunol, Philadelphia, November 10–15, 2006.
6.
Gradman J, Wolthers OD: Allergic conjunctivitis in children with asthma, rhinitis and eczema in a secondary outpatient clinic. Pediatr Allergy Immunol 2006;17:524–526.
7.
Smith AF, Pitt AD, Rodruiguez AE, Alio JL, Marti N, Teus M, Guillen S, Bataille L, Barnes JR: The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 2005;12:233–242.
8.
Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, Bron AJ: Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004;11:17–33.
9.
Bielory L: Role of antihistamine in ocular allergy. Am J Med 2002;113(suppl 9A):34S–37S.
10.
Weiner JM, Abramson MJ, Puy RM: Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ 1998;317:1624–1629.
11.
Nielsen LP, Dahl R: Comparison of intranasal corticosteroids and antihistamines in allergic rhinitis. A review of randomized, controlled trials. Am J Respir Med 2003;2:55–65.
12.
Bernstein DI, Levy AL, Hampel FC, Baidoo CA, Cook CK, Philpot EE, Rickard KA: Treatment with intranasal fluticasone propionate significantly improves ocular symptoms in patients with seasonal allergic rhinitis. Clin Exp Allergy 2004;34:952–957.
13.
Condemi J, Schulz R, Lim J: Triamcinolone acetonide aqueous nasal spray versus loratadine in seasonal allergic rhinitis: efficacy and quality of life. Ann Allergy Asthma Immunol 2000;84:533–538.
14.
Beswick KB, Kenyon GS, Cherry JR: A comparative study of beclomethasone dipropionate aqueous nasal spray with terfenadine tablets in seasonal allergic rhinitis. Curr Med Res Opin 1985;9:560–567.
15.
Wood SF: Oral antihistamine or nasal steroid in hay fever: a double-blind double-dummy comparative study of once daily oral astemizole vs twice daily nasal beclomethasone dipropionate. Clin Allergy 1986;16:195–201.
16.
van Cauwenberge P, Bachert C, Passalacqua G, Bousquet J, Canonica GW, Durham SR, Fokkens WJ, Howarth PH, Lund V, Malling HJ, Mygind N, Passali D, Scadding GK, Wang DY: Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy 2000;55:116–134.
17.
Dykewicz MS, Fineman S: Executive summary of joint task force practice parameters on diagnosis and management of rhinitis. Ann Allergy Asthma Immunol 1998;81:463–468.
18.
Bronsky EA, Aaronson DW, Berkowitz RB, Chervinsky P, Graft D, Kaiser HB, Moss B, Nathan RA, Pearlman DS, Ratner PH, Adelglass JM, Southern DL, van Bavel J, Hampel F, Stricker WE, Fourré JA, Cuss FM, Nolop KB: Dose ranging study of mometasone furoate (Nasonex) in seasonal allergic rhinitis. Ann Allergy Asthma Immunol 1997;79:51–56.
19.
Hebert JR, Nolop K, Lutsky BN: Once-daily mometasone furoate aqueous nasal spray (Nasonex) in seasonal allergic rhinitis: an active- and placebo-controlled study. Allergy 1996;51:569–576.
20.
Gawchik S, Goldstein S, Prenner B, John A: Relief of cough and nasal symptoms associated with allergic rhinitis by mometasone furoate nasal spray. Ann Allergy Asthma Immunol 2003;90:416–421.
21.
Berger WE, Nayak AS, Staudinger HW: Mometasone furoate improves congestion in patients with moderate-to-severe seasonal allergic rhinitis. Ann Pharmacother 2005;39:1984–1989.
22.
Mandl M, Nolop K, Lutsky BN, 194-079 Study Group: Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. Ann Allergy Asthma Immunol 1997;79:370–378.
23.
Anolik R: Clinical benefits of combination treatment with mometasone furoate nasal spray and loratadine vs monotherapy with mometasone furoate in the treatment of seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2008;100:264–271.
24.
Hébert J, Gates D, Danzig M: Mometasone furoate improves total ocular symptom score in patients with allergic rhinitis (abstract 240). J Allergy Clin Immunol 2007;119:S61.
25.
Schenkel E, LaForce C, Gates D: Mometasone furoate nasal spray is effective in relieving the ocular symptoms associated with seasonal allergic rhinitis. Allergy Clin Immunol Int 2007;19:50–53.
26.
Bielory L, Danzig MR, Gates D: Ocular symptoms of seasonal allergic rhinitis can be treated effectively with an intranasal corticosteroid (mometasone furoate nasal spray) (abstract 237). J Allergy Clin Immunol 2007;119:S61.
27.
Bielory L, Danzig MR, Gates D: Ocular (AM and PM) symptoms of seasonal allergic rhinitis improvement with an intranasal corticosteroid (mometasone furoate nasal spray). Poster 1637. 26th Eur Acad Allergol Clin Immunol Congr, Göteborg, 9–13 June 2007.
28.
Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE: Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007;119:1430–1437.
29.
Fokkens WJ, Jogi R, Reinartz S, Sidorenko I, Sitkauskiene B, van Oene C, Faris MA, Ellsworth A, Caldwell MF: Once daily fluticasone furoate nasal spray is effective in seasonal allergic rhinitis caused by grass pollen. Allergy 2007;62:1078–1084.
30.
DeWester J, Philpot EE, Westlund MS, Cook CK, Rickard KA: The efficacy of intranasal fluticasone propionate in the relief of ocular symptoms associated with seasonal allergic rhinitis. Allergy Asthma Proc 2003;24:331–337.
31.
Undem BJ, Kajekar R, Hunter DD, Myers AC: Neural integration and allergic disease. J Allergy Clin Immunol 2000;106:S213–S220.
32.
Baraniuk JN, Silver PB, Kaliner MA, Barnes PJ: Perennial rhinitis subjects have altered vascular, glandular, and neural responses to bradykinin nasal provocation. Int Arch Allergy Immunol 1994;103:202–208.
33.
Riccio MM, Proud D: Evidence that enhanced nasal reactivity to bradykinin in patients with symptomatic allergy is mediated by neural reflexes. J Allergy Clin Immunol 1996;97:1252–1263.
34.
Baroody FM, Wagenmann M, Naclerio RM: Comparison of the secretory response of the nasal mucosa to methacholine and histamine. J Appl Physiol 1993;74:2661–2671.
35.
Salib RJ: Safety and tolerability profiles for intranasal antihistamines and intranasal corticosteroids in the treatment of allergic rhinitis. Drug Safety 2003;26:863–893.
36.
Allen DB: Systemic effects of intranasal steroids: an endocrinologist’s perspective. J Allergy Clin Immunol 2000;106:S179–S190.
37.
Garbe E, LeLorier J, Boivin JF, Suissa S: Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 1997;27:722–727.
38.
Howland WC: Fluticasone propionate: topical or systemic effects? Clin Exp Allergy 1996;26:18–22.
39.
Bross-Soriano D, Hanenberg-Milver C, Schimelmitz-Idi J, Arrieta-Gomez JR, Astorga Del Toro R, Bravo-Escobar G: Effects of three nasal topical steroids in the intraocular pressure compartment. Otolaryngol Head Neck Surg 2004;130:187–191.
40.
Derby L, Maier WC: Risk of cataract among users of intranasal steroids. J Allergy Clin Immunol 2000;105:912–916.
41.
Möller C, Ahlström H, Henricson K-Å, Malmqvist L-Å, Äkerlund A, Hildebrand H: Safety of nasal budesonide in the long-term treatment of children with perennial rhinitis. Clin Exp Allergy 2003;33:816–822.
42.
Rosenblut A, Bardin PG, Muller B, et al: Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 2007;62:1071–1077.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.